SummitTX Capital L.P. Makes New Investment in Genmab A/S Sponsored ADR $GMAB

SummitTX Capital L.P. bought a new stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB) in the first quarter, HoldingsChannel.com reports. The fund bought 84,354 shares of the company’s stock, valued at approximately $2,263,000.

Several other institutional investors also recently made changes to their positions in the stock. EverSource Wealth Advisors LLC raised its position in shares of Genmab A/S by 124.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock worth $44,000 after purchasing an additional 1,174 shares during the period. Sei Investments Co. boosted its position in Genmab A/S by 4.2% during the 2nd quarter. Sei Investments Co. now owns 62,111 shares of the company’s stock valued at $1,283,000 after purchasing an additional 2,496 shares during the period. Squarepoint Ops LLC grew its stake in Genmab A/S by 636.3% during the 2nd quarter. Squarepoint Ops LLC now owns 94,233 shares of the company’s stock worth $1,947,000 after buying an additional 81,434 shares during the last quarter. Quantinno Capital Management LP grew its stake in Genmab A/S by 64.9% during the 2nd quarter. Quantinno Capital Management LP now owns 158,132 shares of the company’s stock worth $3,267,000 after buying an additional 62,226 shares during the last quarter. Finally, Raymond James Financial Inc. grew its stake in Genmab A/S by 48.1% during the 2nd quarter. Raymond James Financial Inc. now owns 31,146 shares of the company’s stock worth $643,000 after buying an additional 10,113 shares during the last quarter. 7.07% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. TD Cowen upgraded Genmab A/S from a “hold” rating to a “buy” rating and raised their target price for the company from $32.00 to $43.00 in a research note on Wednesday, July 22nd. The Goldman Sachs Group upgraded shares of Genmab A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 22nd. BNP Paribas Exane upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, April 22nd. HC Wainwright increased their price objective on shares of Genmab A/S from $38.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, July 2nd. Finally, Weiss Ratings downgraded shares of Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.28.

Genmab A/S Stock Performance

Shares of GMAB stock opened at $29.00 on Wednesday. Genmab A/S Sponsored ADR has a 12-month low of $21.00 and a 12-month high of $35.43. The firm has a market capitalization of $18.08 billion, a price-to-earnings ratio of 21.97, a price-to-earnings-growth ratio of 1.81 and a beta of 0.84. The business has a 50 day simple moving average of $26.93 and a 200 day simple moving average of $28.23. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.18 and a quick ratio of 2.17.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.